A clinical study of Najlant Powder for treating nasal allergy

A Single group open label clinical trial to evaluate the efficacy and safety of Najlant powder in the management of Allergic rhinitis - NIL

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/07/113530

Enrollment

Registered

2026-07-07

Start date

Unknown

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J00-J06- Acute upper respiratory infections

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Adults aged 18 to 65 years Diagnosed cases of Allergic rhinitis History of recurrent cold or seasonal allergy Willig to give written informed consent

Exclusion criteria

Exclusion criteria: Severe respiratory illness or pneumonia Chronic lung disease requiring hospitaliszation Severe systemic illness Pregnant or lactating women

Design outcomes

Primary

Measure	Time frame
Reduction in severity of Allergic rhinitis symptoms and modern parameters AEcC IgE etcTimepoint: Day 0 Day 7 Day 15 Day 30	—

Secondary

Measure	Time frame
NilTimepoint: Nil	—

Countries

India

Contacts

Public ContactDr Nijil A V

Parul institute of Ayurved

dr.nijilav@gmail.com8075706819

Outcome results